22nd Annual Scientific Meeting
18 – 20 February, 2026 // Washington DC
Distinguished Poster Award Recipient:
|
|||
|
Siegel – Precision Imaging Drug Trials: Quantifying the Impact of Study Design on fMRI Biomarker Sensitivity and Statistical Power (Abstract) |
|||
|
All Poster PDFs and Abstracts are available here. |
|||
18 February 2026 |
|||
| Welcome from the President | Luca Pani slides video |
||
| Keynote Address: CDER Office of Neuroscience | Valentina Mantua Michelle Campbell slides video |
||
| New Investigator Award Presentations (Day 1) |
Judith Jaeger slides Jamie Courtland slidesClaire Erickson slidesMorgan Hardy slidesKeiko Kunitoki slidesYoojin Lee slides video – All Presenters |
||
| Methodological opportunities and challenges with long-term post-marketing data | Chairs: Ole Andreassen Jenicka Engler Shaheen Lakhan |
||
| Introduction
|
Jenicka Engler slides video |
||
| Long-term medical outcomes of antipsychotic treatment | Mark Weiser slides video |
||
| Use of large real-world databases: Opportunities and challenges | Ole Andreassen slides video |
||
| Safety trial methodology considerations for novel mechanisms of action in psychiatry trials | Tejendra Patel slides video |
||
| Integrated evidence generation planning: Leveraging AI and real-world evidence to advance science | Mandeep Kaur slides video |
||
| Regulatory perspective | Wei Hua slides video |
||
| Panel Discussion | All speakers Facilitator: Shaheen Lakhan video |
||
|
Wednesday Working Group Sessions |
|||
| Advancing the methods to evaluate abuse and dependence-potential in clinical studies for CNS-active drugs and novel psychedelics | Chairs: Jadwiga Martynowicz Beatrice Setnik slides |
||
| Behavioral and psychiatric symptoms in dementia (BPSD): Apathy/Agitation | Chairs: Krista Lanctôt David Miller summary slides |
||
| Defining and standardizing vocal biomarker outcomes | Chairs: Alex Cohen Jan Sedway slides |
||
| Workshop: Identifying and addressing hurdles to the introduction of new treatments and methodology into clinical practice | Chairs: Larry Alphs Ara Khachaturian summary |
||
| Orphan diseases | Chairs: Joan Busner Gahan Pandina summary slides |
||
| Sleep methodology in CNS trials | Chairs: Georg Dorffner Margaret Moline summary slides |
||
19 February 2026 |
|||
| New Investigator Award Presentations (Day 2) |
Judith Jaeger slides Julia Longenecker slidesZev Nakamura slidesAikaterina Stravoravdi slidesAmy Wegener slides video – All Presenters |
||
| Lewis Alan Opler Prize Presentations | Gary Sachs Mark Opler slidesCecilia Bergeria slidesSunny Tang slides video – All Presenters |
||
| Emerging value and pitfalls of large language models in drug development | Chairs: Anzar Abbas Amir Kalali |
||
| LLMs: Good or bad? | Amir Kalali slides video |
||
| Introduction to session | Anzar Abbas slides video |
||
| Use of LLMs for oversight in a phase 3 clinical development program
|
Todd Solomon slides video |
||
| Automated monitoring of dosing and other sessions in psychedelic trials using LLMs | Atul Mahableshwarkar slides video |
||
| Novel methods to quantify changes in schizophrenia symptoms using PANSS interview transcripts | Jeffrey Cochran slides video |
||
| The application of artificial intelligence/machine learning in drug development and regulation | Ruihao Huang slides video |
||
| Panel Discussion | All speakers Panelist: Valentina Mantua slides video |
||
| Use of regulatory flexibility to accelerate drug development | Chairs: Kemi Olugemo Siân Ratcliffe Smethurst |
||
| Introduction | Kemi Olugemo slides video |
||
| Path to prevention (P2P) therapeutics platform trial in early neuronal synuclein disease (NSD) | Christopher Coffey slides video |
||
| Use of external controls for the primary analysis of a randomized phase 3 study to evaluate a higher dose regimen of nusinersen for the treatment of spinal muscular atrophy (SMA) | Richard Foster* slides |
||
| Prognostic adjustment and other digital twin methods for improving trial efficiency | Roland Brown slides video |
||
| Surrogate endpoint in Alzheimer’s disease | Tianle Chen slides video |
||
| Precision medicine at scale: Operationalizing individualized trials | Sarah Glass slides video |
||
| Panel Discussion
|
All speakers Facilitators: Kemi Olugemo Luca Pani Panelist: Emily Freilich slides video |
||
| The power of inclusion in clinical trials: It’s time to study all people, even if they have thought about suicide | Chairs: Jill Harkavy-Friedman Manish Jha |
||
| Introduction: Goals of session and key issues to be addressed | Jill Harkavy-Friedman slides video |
||
| The goal of clinical trials that include suicidal people is not just prediction of risk | Manish Jha slides video |
||
| Current approach to including individuals with suicidal ideation and behavior (SIB) in clinical trials | Steven Szabo slides video |
||
| Including people with suicidal ideations and behaviors in CNS clinical trials: Regulatory perspectives | Zimri Yaseen slides video |
||
| Panel Discussion with Jha, Szabo, and Yaseen | Panel video |
||
| Psychometric and statistical considerations for including patients with SI/B in clinical trials | Kari Nations slides video |
||
| Implementation of suicide research into clinical settings | Elizabeth Ballard slides video |
||
| Ecological momentary assessment of suicidal ideation and behavior in trials | Evan Kleiman slides video |
||
| Clinically based suicide prevention: Veterans Affairs Health System suicide analytics and the REACH VET clinical program | John McCarthy slides video |
||
| Panel Discussion | All speakers Facilitators: Jill Harkavy-Friedman Manish Jha video |
||
| Poster Session/Reception | Poster PDFs and Abstracts | ||
20 February 2026
|
|||
|
Friday Working Group Sessions |
|||
| Development of novel endpoints for clinical trials in substance use disorders | Chairs: Martin Mumenthaler Tanya Ramey summary slides |
||
| Emerging value and challenges of large language models (LLMs) in drug development | Chairs: Anzar Abbas Amir Kalali |
||
| Estimands and missing data | Chairs: Elena Polverejan Lorenzo Guizzaro summary slides |
||
| Accelerating development of psychopathology measures- ISCTM/ECNP joint working group: Subgroup meetings |
Chairs: Jenicka Engler Nina Schooler Celso Arango |
||
| Bipolar disorder subgroup (Manpreet Singh, Eduard Vieta) | Bipolar subgroup summary | ||
| MDD subgroup (Jenicka Engler, Stephanie Sommer) | MDD subgroup summary | ||
| Schizophrenia subgroup (Anzalee Khan, Armida Mucci, Simon Desjardins) | |||
| Development, validation, and qualification of novel clinical endpoints | Chairs: Adam Butler Sonya Eremenco |
||
| Introduction | Adam Butler slides video |
||
| Development and qualification of the Virtual Reality Functional Capacity Assessment Tool-Short List for early Alzheimer’s disease | Sonya Eremenco slides video |
||
| Qualification plan for the PSYCHS as a ClinRO for attenuated positive symptoms in patients at clinical high risk for psychosis | Scott Woods slides video |
||
| Qualification of depression and anxiety AI-COA through ISTAND | Marc Aafjes slides video |
||
| Patient perspective on clinical trials and rating scales | Emma C. slides video |
||
| Regulatory perspectives: Development and qualification of novel drug development tools | Michelle Campbell slides video |
||
| Panel Discussion | All speakers Facilitator: Adam Butler video |
||
| Meeting Adjourned | Atul Mahableshwarkar slides video |
||
| *Video not released | |||